Camoteskimab - CISMeF

Preferred Label : Camoteskimab;

NCIt synonyms : Anti-IL-18 Monoclonal Antibody CERC-007;

NCIt definition : A human immunoglobulin G1 (IgG1) monoclonal antibody against the pro-inflammatory cytokine interleukin-18 (IL-18), with potential anti-inflammatory and antineoplastic activities. Upon administration, camoteskimab selectively targets and binds to IL-18, thereby inhibiting IL-18-mediated signaling and inflammation mediated by this pathway. In addition, this may inhibit IL-18-mediated immunosuppression in the multiple myeloma microenvironment. IL-18 is a member of the interleukin-1 (IL-1) cytokine superfamily. Elevated IL-18 level is associated with disease progression and poor prognosis in multiple myeloma.;

UNII : ONX021SC9O;

CAS number : 2492472-82-7;

Molecule name : CERC 007; MEDI2338; AEVI-007; CERC-007;

NCI Metathesaurus CUI : CL1662076;

Details

Origin ID

C179215;

UMLS CUI

C5706705;

Currated CISMeF NLP mapping
- Camoteskimab [SMS substance]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
chemical_or_drug_has_mechanism_of_action
- Antigen Binding [NCIt concept]
concept_is_in_subset
- CTRP Agent Terminology [NCIt concept]
- CTRP Terminology [NCIt concept]
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
has_target
- Interleukin-18 [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients